RxDoctor Payments Data

Gary Gordon, MD

Hematology & Oncology · Elk Grove Village, ILNPI 1245291780

Payments from drug & device makers

$22,315in general payments, 2019–2025

Across 595 payments — averaging $37.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Trisalus Life Sciences, Inc.$7K
  • Seagen Inc.$2K
  • Genentech USA, Inc.$1K
  • Merck$1K
  • Novartis$1K
  • Avyxa Pharma, LLC$1K
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$8,38838%
  • Speaking & faculty fees$1,0004%
  • Food & beverage$12,10354%
  • Education$3261%
  • Other$4992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Trisalus Life Sciences, Inc.3$7,013
Seagen Inc.28$1,920
Genentech USA, Inc.80$1,396
Merck66$1,326
Novartis51$1,280
Avyxa Pharma, LLC1$1,000
Johnson & Johnson(2 entities)35$788
AstraZeneca(2 entities)24$621
Pfizer25$424
Pharmacyclics LLC, An Abbvie Company15$371
Incyte Corporation18$354
Lilly USA, LLC13$331
Amgen13$301
Gilead13$262
E.r. Squibb & Sons, L.L.C.11$248
Eisai Inc.11$245
AbbVie7$241
Sanofi11$239
Astellas Pharma US Inc11$229
Daiichi Sankyo Inc.11$226
Novocure Inc.3$196
EMD Serono, Inc.9$190
Servier Pharmaceuticals LLC7$149
Bayer7$147
Jazz Pharmaceuticals Inc.6$147
Regeneron Healthcare Solutions, Inc.4$145
Coherus Oncology, Inc.7$145
G1 Therapeutics, Inc.6$129
Takeda Pharmaceuticals U.S.A., Inc.4$112
Blueprint Medicines Corporation5$108
GSK6$104
Beigene USA, Inc.4$101
Beone Medicines USA, Inc.3$91
Exelixis Inc.4$86
Deciphera Pharmaceuticals Inc.4$83
Pharmacosmos Therapeutics Inc.3$74
Puma Biotechnology, Inc.4$73
Karyopharm Therapeutics Inc.3$70
Tersera Therapeutics LLC2$66
Bristol Myers Squibb3$66
Tesaro, Inc.2$61
Inari Medical, Inc.1$55
Genentech, Inc.1$50
Mirati Therapeutics, Inc.2$50
Tempus AI, Inc2$49
AVEO Pharmaceuticals, Inc.3$49
Morphosys, US Inc.2$48
Agios Pharmaceuticals, Inc.2$47
Foundation Medicine, Inc.2$39
AMAG Pharmaceuticals, Inc.2$38
Apellis Pharmaceuticals, Inc.2$38
Dendreon Pharmaceuticals LLC1$35
Rigel Pharmaceuticals, Inc.1$34
Springworks Therapeutics, Inc.1$33
Pharmaessentia USA Corporation1$33
Syndax Pharmaceuticals, Inc.1$32
Immunocore Limited1$30
Adaptive Biotechnologies Corporation1$28
Sobi, Inc1$28
Stemline Therapeutics Inc.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,315 in reported general payments places this provider in the 60th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,793,757
Medicare patients
608
Services billed
181,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide18$407,169
RevlimidLenalidomide23$406,933
ImbruvicaIbrutinib11$179,158
Lenalidomide19$171,074
EliquisApixaban108$91,067
XareltoRivaroxaban73$61,436
VenclextaVenetoclax11$52,383
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$1,377
Anastrozole42$791
Enoxaparin Sodium16$739
Hydroxyurea15$634
Dexamethasone38$452
Levothyroxine Sodium74$425
Prochlorperazine Maleate25$390
Gabapentin43$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$248$407,16918 claims
Bristol Myers SquibbRevlimid$66$406,93323 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$371$179,15811 claims
PfizerEliquis$424$91,067108 claims
Johnson & JohnsonXarelto$788$61,43673 claims
AbbVieVenclexta$241$52,38311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →